2025-02-11 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**0. Summary Statistics:**

VRTX, Vertex Pharmaceuticals Inc., is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.

* **Cumulative Return (VRTX):** 165.73%
* **Cumulative Return (VOO):** 120.05%
* **Return Difference (VRTX - VOO):** 45.68%
* **Relative Divergence:** 70.0% (indicates VRTX outperformed VOO significantly relative to historical data)


**1. Performance Analysis:**

VRTX has significantly outperformed the S&P 500 (VOO) over the analyzed period, with a cumulative return considerably higher than VOO's.  The relative divergence of 70% suggests this outperformance is substantial compared to the historical range of its performance relative to the S&P 500. The provided alpha values generally indicate consistent outperformance compared to the market benchmark, except during the 2019-2021 period.  Beta values generally show moderate sensitivity to market movements but this sensitivity increases from 2017 onwards.  Market capitalization increased significantly throughout the period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 48.0% | 21.7% | 19.0% | 0.1 | 38.6 |
| 2016-2018  | 66.0% | 11.0% | 47.0% | 0.1 | 42.7 |
| 2017-2019  | 88.0% | 11.0% | 57.0% | 0.6 | 56.4 |
| 2018-2020  | 17.0% | 22.8% | -10.0% | 0.2 | 60.9 |
| 2019-2021  | -9.0% | 22.8% | -80.0% | 0.2 | 56.5 |
| 2020-2022  | 10.0% | 22.8% | 2.0% | 0.2 | 74.4 |
| 2021-2023  | 84.0% | 9.6% | 60.0% | 0.5 | 104.8 |
| 2022-2024  | 64.0% | 13.7% | 31.0% | 0.5 | 103.7 |
| 2023-2025  | 57.0% | 13.7% | -3.0% | 0.5 | 121.0 |


**2. Recent Price Movement:**

* **Closing Price:** $469.97
* **5-Day Moving Average:** $478.23
* **20-Day Moving Average:** $445.56
* **60-Day Moving Average:** $444.69

The price is currently below its 5-day moving average, suggesting a recent slight downturn.  However, it sits above both the 20-day and 60-day moving averages, indicating a potential upward trend in the medium to long term.


**3. Technical Indicators:**

* **RSI (72.58):**  Approaching overbought territory, suggesting potential near-term correction.
* **PPO (0.94):** Positive value indicates bullish momentum.
* **20-Day Relative Divergence Change (-1.7):**  Indicates a recent short-term decline in relative strength.
* **Expected Return (18%):**  Significant potential long-term (2+ years) outperformance relative to the S&P 500 is projected.  This should be interpreted cautiously, as future returns are inherently uncertain.
* **Price Change:**  A small positive daily change (0.14%) is observed. This is not significant enough to be considered a rapid price movement.


**4. Recent Earnings Analysis:**

The earnings data shows significant volatility.  There's a large negative EPS in August 2024 (-13.92), which significantly impacts the average. While revenue is relatively consistent, the EPS fluctuation warrants further investigation.  Itâ€™s crucial to understand the reasons behind this volatility (e.g., one-time charges, seasonal factors) before drawing definitive conclusions.

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2024-11-05 | 4.05  | $2.77 B     |
| 2024-08-02 | -13.92 | $2.65 B     |
| 2024-05-07 | 4.26  | $2.69 B     |
| 2023-11-07 | 4.01  | $2.48 B     |
| 2024-11-05 | 4.01  | $2.48 B     |


**5. Financial Information:**

The financial data displays strong revenue growth and high profit margins consistently.  However, the Return on Equity (ROE) shows volatility. The negative ROE in Q2 2024 requires further investigation to determine the underlying cause.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $2.77B | 85.84% |
| 2024-06-30 | $2.65B | 85.94% |
| 2024-03-31 | $2.69B | 87.27% |
| 2023-12-31 | $2.52B | 85.38% |
| 2023-09-30 | $2.48B | 87.17% |

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $15.63B | 6.69% |
| 2024-06-30 | $14.77B | -24.32% |
| 2024-03-31 | $18.55B | 5.93% |
| 2023-12-31 | $17.58B | 5.51% |
| 2023-09-30 | $16.51B | 6.27% |


**6. Overall Analysis:**

VRTX exhibits a strong track record of outperformance against the S&P 500, supported by generally positive alpha values and relatively consistent revenue and high profit margins. However, the recent earnings data shows volatility in EPS, and the ROE needs further investigation to understand the fluctuations.  The technical indicators suggest a potential short-term correction but overall bullish momentum.  The projected long-term outperformance should be viewed with caution, considering inherent market uncertainties.  Further research into the causes of the EPS volatility and negative ROE is recommended before making any investment decisions.  It's also vital to consider factors beyond the provided data (e.g., competitive landscape, regulatory hurdles, pipeline prospects) before formulating a comprehensive investment strategy.
